Primary nocturnal enuresis (PNE) is one of the most frequent complaints in pediatric practice. Several different factors such as reduced functional bladder capacity, and endocrinological and neurological disorders are attributed to PNE. [1] [2] [3] The use of desmopressin (DDAVP), a synthetic analogue of the endogenous hormone arginine vasopressin, for the treatment of nocturnal enuresis is based on its antidiuretic action. 4 Desmopressin binds to the renal V 2 -receptor located at the basolateral side of renal cortical collecting duct cells. This leads to a cyclic adenosine monophosphate mediated insertion of the waterchannel aquaporin-2 into the apical membrane and subsequent reabsorption of H 2 O. 5 However, recent studies provided evidence that desmopressin influences other renal transport systems as well.
In vivo studies demonstrated that arginine vaspression regulates the abundance of the furosemide sensitive sodium-2 chloride-potassium channel. 6 Other sodium transporters, such as the amiloride sensitive epithelial sodium channel, have also been shown to be regulated by desmopressin. 7 Moreover, use of gene expression profiling has shown that molecules not directly involved in transport processes are influenced by desmopressin administration. 8 These data implicate that desmopressin has far more complex primary or secondary regulatory activity on several renal transport systems than anticipated.
Since desmopressin proved to be an effective agent for PNE, its use is widely accepted but studies concerning the influence of this drug on renal ion handling in children with PNE are lacking. Especially for the mid-term and long-term use of desmopressin, it is not known whether this drug has other than isolated antidiuretic effects. This question is of special importance in children since several molecules are essential to guarantee adequate growth and development. Valenti et al demonstrated close correlation between hypercalciuria and aquaporin-2 excretion in children with PNE. 9 Likewise, the same authors were able to demonstrate a reduction in nocturnal enuresis episodes in hypercalciuric children when treated with a low calcium diet and desmopressin. 10 Controversely, Nevéus et al were not able to find a significant difference between the Ca 2ϩ excretion in children with PNE and controls. 11 Therefore, we evaluate whether desmopressin treatment influences urinary excretion of Ca 2ϩ in children with PNE.
PATIENTS AND METHODS
Enuresis was defined by 3 or more wet nights a week. The study included 15 girls and 17 boys 6.2 to 16.5 years old (median age 9.8) with primary nocturnal enuresis who had never been dry for longer than 3 months and had no daytime symptoms. No patient had received drug therapy for enuresis before entering the study. Diagnosis was confirmed by exclusion of anatomical abnormalities on ultrasound, and unremarkable urinalysis and serum analysis.
Patients received the standard 30 g desmopressin intranasally before going to bed for at least 4 weeks. Desmopressin was then withdrawn, reintroduced after 2 weeks and continued for at least another 3 weeks. Urine samples were collected at the end of all 3 phases of the study. Ca 2ϩ measurement was performed in single morning spot urines of 2 consecutive days as well as in 24-hour collections. The parents were asked to ensure that the collections were performed on dry nights. Additionally, blood was sampled for analysis of Ca 2ϩ . The data are given as arithmetic mean with standard deviation, median, 95% confidence interval of the median and range. Differences were tested using the nonparametric Wilcoxon signed rank test, with p ϭ 0.05 considered significant.
RESULTS
Without therapy the children had 4.75 wet nights per week versus 1 per week with desmopressin (p Ͻ0.001). During the first 4 weeks of desmopressin therapy, withdrawal and second therapy course serum Ca 2ϩ did not change significantly and remained in the range of normal, healthy children.
Urinary Ca 2ϩ excretion per 24 hours decreased significantly during the first desmopressin (DDAVP) therapy (p ϭ 0.048) and withdrawal, and increased with reintroduction of desmopressin (p ϭ 0.044, table 1). The differences in Ca 2ϩ -concentrations in the morning spot urines between therapy and withdrawal conditions were even more distinct. The creatinine related concentration measured in the first 4 weeks of therapy was 303 mol/mmol and decreased without therapy to 262 mol/mmol, which was significant (p ϭ 0.047). At restart of therapy the Ca 2ϩ -concentration increased significantly to 364 mol/mmol (p ϭ 0.003, table 2).
DISCUSSION
In this prospective study we confirmed that desmopressin in children with PNE influences urinary Ca 2ϩ excretion. We reproduced the beneficial effect of desmopressin on nocturnal enuresis as wet nights decreased from 4.75 to 1.0 per week. According to our experiences and those published in the literature, the overall success rate of desmopressin treatment ranges from 35% to 65%. 12 This success is comparable to other treatments used for PNE, such as the bell pad and tricyclic antidepressants (eg imipramine). 13, 14 From this point of view, our patients did not differ from others with PNE and, therefore, were considered as a standard patient group for this study.
From our prospective study we learned that desmopressin increases urinary Ca 2ϩ excretion in children with PNE. This finding was unexpected, since studies of primary cultures of rabbit distal nephron cells showed increased transcellular Ca 2ϩ transport. 15 In addition to these renal effects, there is evidence of nonrenal effects in the treatment of PNE. 16, 17 From the clinical point of view it has been known for a long time that hypercalciuria is an important cause of frequent voiding and dysuria in children. 18 It is also established that hypercalciuria is one of the most frequent causes of microhematuria in childhood. 19 The influence of hypercalciuria on PNE itself has been demonstrated. 20 The hypothesis for this symptom is that microcrystallization of Ca 2ϩ , PO 4 3Ϫ and oxalate occurs and causes microtrauma and irritation to the urethral and bladder mucosa, which is followed by spontaneous contractions and bladder emptying.
Our prospective study, which was controlled by withdrawal and reintroduction of desmopressin, is to our knowledge the first to describe renal Ca 2ϩ handling during desmopressin treatment in children with PNE. While in vitro and animal studies suggest a positive effect of desmopressin on renal tubular Ca 2ϩ reabsorption, our findings demonstrate the opposite effect in humans. To rule out the possibility that increased urinary Ca 2ϩ values were just a result of a more concentrated urine, we measured Ca 2ϩ excretion as the ratio of urinary Ca 2ϩ and urinary creatinine (spot urines), and we obtained complete 24-hour urine samples and calculated absolute Ca 2ϩ excretion daily. For both methods we obtained a slight but significant increase in urinary Ca 2ϩ excretion while children were treated with desmopressin. In 30 of the 32 cases urinary Ca 2ϩ excretion stayed within the normal range with and without desmopressin treatment. The remaining 2 patients already had hypercalciuria which was aggravated by desmopressin.
These data support the finding that desmopressin causes more than a simple antidiuretic effect by renal water reabsorption. Accordingly, Ca 2ϩ must be added to the list of molecules that are influenced by desmopressin. This finding requires further investigation since Ca 2ϩ is a crucial molecule in growth and development. Although desmopressin treatment did not increase Ca 2ϩ excretion dramatically, the difference is significant if a long-term treatment is considered. Compensation mechanisms for renal Ca 2ϩ loss include increased intestinal reabsorption but also Ca 2ϩ resorption from bone.
CONCLUSIONS
Based on these findings, we include urinary Ca 2ϩ excretion before and during treatment of PNE into the routine diagnostic followup. Long-term followup studies are needed to clarify the impact of desmopressin on Ca 2ϩ excretion in children with PNE concerning different parameters such as bone densitometry, parathyroid hormone, osteocalcin or calcitonin. 
